Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 18, 2026, titled "Glenmark Pharmaceuticals Inc., USA Launches Vancomycin Hydrochloride for Injection USP, 500mg/vial and 1 g/vial".
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Glenmark Pharmaceuticals Inc., USA (the US subsidiary) has announced the launch of Vancomycin Hydrochloride for Injection USP in two dosage strengths (500mg/vial and 1g/vial). The product is bioequivalent and therapeutically equivalent to Fresenius Kabi USA's reference listed drug. According to IQVIA sales data for the 12-month period ending March 2026, the US market for this injectable antibiotic totals approximately $37.9 million annually. This launch expands Glenmark's US injectable portfolio and aligns with the company's strategy to provide affordable generic medicines in the American market.
The launch represents new revenue potential for Glenmark in the US generics market, a key region for the company. While the $37.9 million addressable market is moderate, successful penetration could contribute positively to the company's US revenues over time.